External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Inflammatory Disease ACG 2024
Roche and Genentech at

ACG 2024

October 25 - October 30
Philadelphia, USA / Virtual (Hybrid)
acgmeetings.gi.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
02:10 PM
Duration 10mins Philadelphia, USA
TUSCANY-2: A Dose-Ranging Phase IIb Study Evaluating Efficacy and Safety of RO7790121, an Antibody Against Tumor Necrosis Factor-like Ligand 1A (Anti-TL1A) in Adults with Moderately to Severely Active Ulcerative Colitis
Danese S, Allegretti JR, Schreiber S, Peyrin-Biroulet L, Jairath V, D'Haens G, Kierkus J, Leong RW, Yarur A, McBride J, Bojic D, Lasch K, Schiffman C, Feagan BG
Inflammatory Disease | Inflammatory Bowel Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.